Part IOrderVolume 158, Number 23Published: June 8, 2024
Processed Cannabis Plant Derivatives Added
Canada Gazette, Part I, Volume 158, Number 23: Order Amending Schedule 2 to the Cannabis Act
REGULATORY IMPACT ANALYSIS STATEMENT
Key facts
- Published
- June 8, 2024
- Comment deadline
- July 8, 2024
- Effective date
- Unclear
Summary#
This is a proposed Order Amending Schedule 2 to the Cannabis Act published on June 8, 2024. It would add a new entry to Schedule 2 of the Cannabis Act to cover certain processed plant derivatives that do not contain isolated or concentrated phytocannabinoids. The government is accepting comments for 30 days.
What it does#
- Adds item 5 to Schedule 2 of the Cannabis Act. The new wording covers "a derivative made by processing plant parts referred to in items 1 to 4, or a product made from that derivative, that does not contain an isolated or concentrated phytocannabinoid."
- The change is set out as a proposed Order Amending Schedule 2 to the Cannabis Act. It is published as a consultation (Part I) item; it is not yet in force.
- Interested people and businesses may send representations to the Department of Health within 30 days of the notice (contact details are given in the Canada Gazette posting).
- If finalized, the Order would come into force on the day it is published in Canada Gazette, Part II.
Who's affected#
- Companies that process cannabis or hemp plant parts and make derivatives or products from those derivatives.
- Manufacturers, retailers, or importers of processed cannabis/hemp products that do not contain isolated or concentrated phytocannabinoids.
- Regulators and legal advisers who interpret which products fall inside or outside the scope of the Cannabis Act.
- It is not perfectly clear from this notice which specific products will be affected; stakeholders are being invited to comment.
Why it matters#
- The change aims to clarify which processed plant derivatives are treated differently under the Cannabis Act. That can affect whether a product needs a cannabis licence or is subject to cannabis rules.
- For businesses, the amendment could reduce uncertainty about regulatory requirements for certain hemp/cannabis-derived products that do not contain isolated or concentrated phytocannabinoids.
- The 30-day comment period gives affected parties a chance to tell the government if the wording needs to be clearer or if it would have unintended effects.
Key topics
Cannabis ActSchedule 2isolated or concentrated phytocannabinoidphytocannabinoidprocessed plant derivativehemp productscannabis regulationDepartment of HealthHealth CanadaControlled Substances and Cannabis Branchcannabis licensing30-day comment period
Source: Canada Gazette